The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: Insights into the natural history of hepatitis C virus infection and implications for donor counseling

Transfusion

Volumn 52, Issue 9, 2012, Pages 1940-1948

  Makuria, Addisalem T ^a,b,c,d   Raghuraman, Sukanya ^a,b,c,d   Burbelo, Peter D ^a,b,c,d   Cantilena, Cathy C ^a,b,c,d   Allison, Robert D ^a,b,c,d   Gibble, Joan ^a,b,c,d   Rehermann, Barbara ^a,b,c,d   Alter, Harvey J ^a,b,c,d  

^a Infectious Disease Section   (United States)

^b National Institute for Diabetes and Digestive and Kidney Diseases   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD DONOR; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KIDNEY DONOR; LIQUID LUCIFERASE IMMUNOPRECIPITATION SYSTEM; MALE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECOMBINANT IMMUNOBLOT ASSAY; RISK FACTOR; VIRUS CARRIER;

ADULT; ANTIGEN-ANTIBODY REACTIONS; ASYMPTOMATIC DISEASES; BLOOD DONORS; DIAGNOSIS, DIFFERENTIAL; DIRECTIVE COUNSELING; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84865759192     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03524.x     Document Type: Article

References (25)

1. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE,. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73.
3. Williams I,. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S.
4. Sy T, Jamal MM,. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41-6.
5. Busch MP, Tobler LH, Tegtmeier G, Polito A, Quan S, Hirschler NV, Dockter J, Giachetti C, Mimms L,. Use of third-generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and second-generation recombinant immunoblot assay-indeterminate blood samples: data to support current Food and Drug Administration guidance on HCV lookback. Transfusion 2000; 40: 10-4.
6. Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, Sayada C, Duval J, Dhumeaux D,. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996; 34: 80-3.
7. Hitziger T, Schmidt M, Schottstedt V, Hennig H, Schumann A, Ross S, Lu M, Seifried E, Roggendorf M,. Cellular immune response to hepatitis C virus (HCV) in nonviremic blood donors with indeterminate anti-HCV reactivity. Transfusion 2009; 49: 1306-13.
8. Burbelo PD, Ching KH, Bren KE, Ladarola MJ,. Searching for biomarkers: humoral response profiling with Luciferous Immunoprecipitation System (LIPS). Expert Rev Proteomics 2011; 8: 309-16.
9. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B,. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
10. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B,. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-58.
11. Rehermann B,. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-54.
12. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MD,. Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J Vis Exp 2009;(32): pii: 1549, [cited 2009 Oct 7]. Available from: URL: http://www.jove.com/index/Details.stp? ID=1549:doi:10.3791/1549
13. Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA, Kottilil S,. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. J Infect Dis 2010; 202: 894-8.
14. Alter MJ,. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-5S.
15. Heintges T, Wands JR,. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26: 521-6.
16. CDC. Hepatitis C FAQs for health professionals (monograph on the internet). 2009.
17. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M,. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
18. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS,. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
19. Schuttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S,. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000; 355: 41-2.
20. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P,. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-8.
21. Pawlotsky JM, Fleury A, Choukroun V, Deforges L, Roudot-Thoraval F, Aumont P, Duval J, Dhumeaux D,. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J Clin Microbiol 1994; 32: 1357-9.
22. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, Kaslow R, Ness P, Alter HJ,. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
23. Bes M, Esteban JI, Casamitjana N, Piron M, Quer J, Cubero M, Puig L, Guardia J, Sauleda S,. Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion 2009; 49: 1296-305.
24. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L,. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.
25. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR,. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.